Aspirin (lithium)

Aspirin (lithium)

• CAS Number: 552-98-7
• UNSPSC Description: Aspirin (Acetylsalicylic Acid) lithium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin lithium induces apoptosis. Aspirin lithium inhibits the activation of NF-κB. Aspirin lithium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis[1][2][3][4][5][6].
• Target Antigen: Apoptosis; Autophagy; Caspase; COX; Mitophagy; NF-κB; p38 MAPK; Virus Protease
• Type: Reference compound
• Related Pathways: Anti-infection;Apoptosis;Autophagy;Immunology/Inflammation;MAPK/ERK Pathway;NF-κB
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease
• Assay Protocol: https://www.medchemexpress.com/aspirin-lithium.html
• Solubility: 10 mM in DMSO
• Smiles: O=C(O[Li])C1=CC=CC=C1OC(C)=O
• Molecular Weight: 186.09
• References & Citations: [1]Mitchell JA, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and induciblecyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7.|[2]Blanco FJ, et al. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73.|[3]Wu KK, et al. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12.|[4]Kopp E, et al. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994 Aug 12;265(5174):956-9.|[5]Burch JW, et al. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978 Feb;61(2):314-9.|[6]Elwood PC, et al. Aspirin, salicylates, and cancer. Lancet. 2009 Apr 11;373(9671):1301-9.|[7]Loux JJ, DePalma PD, Yankell SL. Antipyretic testing of aspirin in rats. Toxicol Appl Pharmacol. 1972 Aug;22(4):672-5.
• Shipping Conditions: Room temperature
• Clinical Information: Launched